Radiation-/hypoxia-induced solid tumor metastasis and regrowth inhibited by hypoxia-specific upconversion nanoradiosensitizer

Biomaterials

Volumn 49, Issue , 2015, Pages 1-8

  Liu, Yanyan ^a   Liu, Yong ^b   Bu, Wenbo ^a   Xiao, Qingfeng ^a   Sun, Yong ^b   Zhao, Kuaile ^b   Fan, Wenpei ^a   Liu, Jianan ^a   Shi, Jianlin ^a  

^a SHANGHAI INSTITUTE OF CERAMICS   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Hypoxia; Metastasis; Nanoradiosensitizer; Radiotherapy; Tumor regrowth

Indexed keywords

CELLS; DISEASES; DRUG DOSAGE; PATHOLOGY; RADIATION PROTECTION; SILICA; TUMORS;

ANTITUMOR EFFECT; CYTOTOXIC AGENTS; HYPOXIA; IONIZING IRRADIATION; MESOPOROUS SILICA; METASTASIS; NANORADIOSENSITIZER; UPCONVERSION NANOPARTICLES;

RADIOTHERAPY;

CYTOTOXIN; SILICON DIOXIDE; TIRAPAZAMINE; UPCONVERSION NANOPARTICLE; NANOPARTICLE; OXYGEN; RADIOSENSITIZING AGENT; TRIAZINE DERIVATIVE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL HYPOXIA; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MICROEMULSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; REOXYGENATION; SOLID TUMOR; TUMOR RESISTANCE; UTERINE CERVIX CARCINOMA; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELL LINE; METABOLISM; METASTASIS; NEOPLASMS; NUDE MOUSE; PATHOLOGY; ULTRASTRUCTURE;

ANIMALS; ANOXIA; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR MATRIX; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASM METASTASIS; NEOPLASMS; OXYGEN; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 84924495324     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.028     Document Type: Article

References (42)

1. Sherwood L., Parris E., Folkman J. Tumor angiogenesis - therapeutic implications. New Engl J Med 1971, 285:1182.
2. Aznavoorian S., Murphy A., Stetlerstevenson W., Liotta L. Molecular aspects of tumor-cell invasion and metastasis. Cancer 1993, 71:1368-1383.
3. Zhang L., Chen W., Li X. Anovel anticancer effect of butein: inhibition of invasion through the ERK1/2 and NF-kappa B signaling pathways in bladder cancer cells. Febs Lett 2008, 582:1821-1828.
4. Madani I., De Neve W., Mareel M. Does ionizing radiation stimulate cancer invasion and metastasis?. Cancer 2008, 95:292-300.
5. Moulder J., Rockwell S. Tumor hypoxia - its impact on cancer therapy. Cancer Metastasis Rev 1987, 5:313-341.
6. Swift M., Taketa S., Bond V. Regionally fractionated X-irradiation equivalent in dose to total body exposure. Radiat Res 1954, 1:241-252.
7. Janssens G., Rademakers S., Terhaard C., Doornaert P., Bijl H., Ende P., et al. Accelerated aadiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 1998, 48:115-122.
8. Kaur P., Hurwitz M., Krishnan S., Asea A. Combined hyperthermia and radiotherapy for the treatment of cancer. Cancer 2011, 3:3799-3823.
9. Fan W., Shen B., Bu W., Chen F., Zhao K., Zhang S., et al. Rattle-structured multifunctional nanotheranostics for synergetic chemo-/radiotherapy and simultaneous magnetic/luminescent dual-mode imaging. JAm Chem Soc 2013, 135:6494-6503.
10. Xiao Q., Zheng X., Bu W., Ge W., Zhang S., Chen F., et al. Acore/satellite multifunctional nanotheranostic for invivo imaging and tumor eradication by radiation/photothermal synergistic therapy. JAm Chem Soc 2013, 135:13041-13048.
11. Teicher B. Hypoxia and drug-resistance. Cancer Metastasis Rev 1994, 13:139-168.
12. Adams G., Hasan N., Joiner M. Radiation, hypoxia and genetic stimulation: implications for future therapies. Radiother Oncol 1997, 44:101-109.
13. Harris A. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
14. Wouters B., Weppler S., Koritzinsky M., Landuyt W., Nuyts S., Theys J., et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002, 38:240-257.
15. Brown J. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002, 1:453-458.
16. Thews O., Wolloscheck T., Dillenburg W., Kraus S., Kelleher D., Konerding M., et al. Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia. Brit J Cancer 2004, 91:1181-1189.
17. Brown J. SR-4233 (Tirapazamine) - a new anticancer drug exploiting hypoxia in solid tumors. Brit J Cancer 1993, 67:1163-1170.
18. Chen Y., Chen H., Shi J. Invivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater 2013, 25:3144-3176.
19. Rodel F., Hoffmann J., Distel L., Herrmann M., Noisternig T., Papadopoulos T., et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65:4881-4887.
20. Chen H., Lee J., Huang J., Wang C., Chen W., Su S., et al. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 2008, 68:7428-7438.
21. 3+-ion-doped upconversion nanoprobes: relaxivity mechanism probing and sensitivity optimization. Adv Funct Mater 2013, 23:298-307.
22. Li X., He Q., Shi J. Global gene expression analysis of cellular death mechanisms induced by mesoporous silica nanoparticle-based drug delivery system. Acs Nano 2014, 8:1309-1320.
23. Siim B., Menke D., Dorie M., Brown J. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 1997, 57:2922-2928.
24. Shuryak I., Hahnfeldt P., Hlatky L., Sachs R., Brenner D. Anew view of radiation-induced cancer: integrating short- and long-term processes. Radiat Environ Biophys 2011, 50:607-608.
25. Howardflanders P., Scott O. Tissue oxygen tension and radiotherapy - a review and bibliography based on a conference in Burlington, Vermont, August 1958. Radiology 1960, 74:956-963.
26. Howardflanders P., Wright E. Effect of oxygen on the radiosensitivity of growing bone and a possible danger in the use of oxygen during radiotherapy. Nature 1955, 175:428-429.
27. Barrallo-Gimeno A., Nieto M. The snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005, 132:3151-3161.
28. Peansukmanee S., Vaughan-Thomas A., Carter S., Clegg P., Taylor S., Redmond C., et al. Effects of hypoxia on glucose transport in primary equine chondrocytes invitro and evidence of reduced GLUT1 gene expression in pathologic cartilage invivo. JOrthop Res 2009, 27:529-535.
29. Vaupel P., Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004, 9:4-9.
30. Biswal N., Pavlik C., Smith M., Aguirre A., Xu Y., Zanganeh S., et al. Imaging tumor hypoxia by near-infrared fluorescence tomography. JBiomed Opt 2011, 16.
31. Fan W., Shen B., Bu W., Chen F., He Q., Zhao K., et al. Asmart upconversion-based mesoporous silica nanotheranostic system for synergetic chemo-/radio-/photodynamic therapy and simultaneous MR/UCL imaging. Biomaterials 2014, 35:8992-9002.
32. Chang M., Shiau A., Chen Y., Chang C., Chen H., Wu C. Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice. Cancer Sci 2008, 99:1479-1484.
33. Jin H., Yu Y., Zhang T., Zhou X., Zhou J., Jia L., et al. Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int J Cancer 2010, 126:2102-2111.
34. Heilig C., Brosius F., Siuat B., Concepcion L., Mortensen R., Heilig K., et al. Implications of glucose transporter protein type 1 (GLUT1)-hapiodeficiency in embryonic stem cells for their survival in response to hypoxic stress. Am J Pathol 2003, 163:1873-1885.
35. Xing H., Zheng X., Ren Q., Bu W., Ge W., Xiao Q., et al. Computed tomography imaging-guided radiotherapy by targeting upconversion nanocubes with significant imaging and radiosensitization enhancements. Sci Rep 2013, 3.
36. Xiao Q., Bu W., Ren Q., Zhang S., Xing H., Chen F., et al. Radiopaque fluorescence-transparent TaOx decorated upconversion nanophosphors for invivo CT/MR/UCL trimodal imaging. Biomaterials 2012, 33:7530-7539.
37. Xing H., Bu W., Zhang S., Zheng X., Li M., Chen F., et al. Multifunctional nanoprobes for upconversion fluorescence, MR and CT trimodal imaging. Biomaterials 2012, 33:1079-1089.
38. Ni D., Zhang J., Bu W., Xing H., Han F., Xiao Q., et al. Dual-targeting upconversion nanoprobes across the blood-brain barrier for magnetic resonance/fluorescence imaging of intracranial glioblastoma. Acs Nano 2014, 8:1231-1242.
39. Apel A., Herr I., Schwarz H., Rodemann H., Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008, 68:1485-1494.
40. Idris N., Gnanasammandhan M., Zhang J., Ho P., Mahendran R., Zhang Y. Invivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat Med 2012, 18:1580.
41. Wang C., Tao H., Cheng L., Liu Z. Near-infrared light induced invivo photodynamic therapy of cancer based on upconversion nanoparticles. Biomaterials 2011, 32:6145-6154.
42. Liu J., Bu W., Pan L., Shi J. NIR-triggered anticancer drug delivery by upconverting nanoparticles with integrated azobenzene-modified mesoporous silica. Angew Chem Int Ed 2013, 52:4375-4379.